共 50 条
- [1] The NKG2A immune checkpoint — a new direction in cancer immunotherapy[J]. Nature Reviews Clinical Oncology, 2019, 16 : 277 - 278Benjamin C. CreelanScott J. Antonia
- [2] The NKG2A immune checkpoint - a new direction in cancer immunotherapy[J]. NATURE REVIEWS CLINICAL ONCOLOGY, 2019, 16 (05) : 277 - 278Creelan, Benjamin C.Antonia, Scott J.
- [3] NKG2A Blockade Potentiates CD8 T Cell Immunity Induced by Cancer Vaccines[J]. CELL, 2018, 175 (07) : 1744 - +van Montfoort, NadineBorst, LindaKorrer, Michael J.Sluijter, MarjoleinMarijt, Koen A.Santegoets, Saskia J.van Ham, Vanessa J.Ehsan, IlinaCharoentong, PornpimolAndre, PascaleWagtmann, NicolaiWelters, Marij J. P.Kim, Young J.Piersma, Sytse J.van der Burg, Sjoerd H.van Hall, Thorbald
- [4] NKG2A immune checkpoint blockade enhances the anti-tumor efficacy of PD1/PD-L1 inhibitors in a preclinical model[J]. CANCER RESEARCH, 2016, 76Sola, CarolineArnoux, ThomasChanuc, FabienFuseri, NicolasRossi, BenjaminGauthier, LaurentLeget, CorinneBonnafous, CecileWagtmann, NicolaiMorel, YannisAndre, Pascale
- [5] NKG2A Immune Checkpoint in Vδ2 T Cells: Emerging Application in Cancer Immunotherapy[J]. CANCERS, 2023, 15 (04)Cazzetta, ValentinaDepierreux, DelphineColucci, FrancescoMikulak, JoannaMavilio, Domenico
- [6] NKG2A and HLA-E define an additional immune checkpoint axis in bladder cancer[J]. EUROPEAN JOURNAL OF IMMUNOLOGY, 2021, 51 : 53 - 53Salome, BerengereSfakianos, John P.Daza, JorgeCharap, AndrewFarkas, Adam M.Geanon, DanielKelly, GeoffreyDe Real, Ronaldo M.Lee, BrianBeaumont, Kristin G.Shroff, SanjanaWang, Ying ChihWang, Yuan ShuoWang, LiSebra, Robert P.Romero, PedroBrody, RachelCarrington, MaryWiklund, PeterMehrazin, RezaGalsky, Matthew D.Bhardwaj, NinaHorowitz, Amir
- [7] NKG2A and HLA-E define an alternative immune checkpoint axis in bladder cancer[J]. CANCER CELL, 2022, 40 (09) : 1027 - +Salome, BerengereSfakianos, John P.Ranti, DanielDaza, JorgeBieber, ChristineCharap, AndrewHammer, ChristianBanchereau, RomainFarkas, Adam M.Ruan, Dan FuIzadmehr, SudehGeanon, DanielKelly, GeoffreyReal, Ronaldo M. deLee, BrianBeaumont, Kristin G.Shroff, SanjanaWang, Yuanshuo A.Wang, Ying-chihThin, Tin HtweGarcia-Barros, MonicaHegewisch-Solloa, EverardoMace, Emily M.Wang, LiO'Donnell, TimothyChowell, DiegoFernandez-Rodriguez, RubenSkobe, MihaelaTaylor, NicoleKim-Schulze, SeungheeSebra, Robert P.Palmer, DougClancy-Thompson, EleanorHammond, ScottKamphorst, Alice O.Malmberg, Karl-JohanMarcenaro, EmanuelaRomero, PedroBrody, RachelViard, MathiasYuki, YukoMartin, MaureenCarrington, MaryMehrazin, RezaWiklund, PeterMellman, IraMariathasan, SanjeevZhu, JunGalsky, Matthew D.Bhardwaj, Nina
- [8] NKG2A AND HLA-E DEFINE A NOVEL ALTERNATIVE IMMUNE CHECKPOINT AXIS IN BLADDER CANCER[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2021, 9 : A338 - A338Salome, BerengereSfakianos, JohnCharap, AndrewFarkas, AdamGeanon, DanielKelly, Geoffreyde Real, RonaldoLee, BrianBeaumont, KristinShroff, SanjanaWang, Ying-ChihWang, Yuan-ShuoWang, LiSebra, RobertKamphorst, AliceMalmberg, Karl-JohanMarcenaro, EmanuelaRomero, PedroBrody, RachelYuki, YukoMartin, MaureenCarrington, MaryMehrazin, RezaWiklund, PeterZhu, JunGalsky, MatthewBhardwaj, NinaHorowitz, Amir
- [9] NKG2A and HLA-E define a novel alternative immune checkpoint axis in bladder cancer[J]. CANCER IMMUNOLOGY RESEARCH, 2022, 10 (01)Salome, BerengereSfakianos, John P.Daza, JorgeCharap, AndrewFarkas, Adam M.Geanon, DanielKelly, GeoffreyDe Real, Ronaldo M.Lee, BrianBeaumont, Kristin G.Shroff, SanjanaWang, Ying-ChinWang, Yuan-Shuo A.Wang, LiSebra, Robert P.Kamphorst, Alice O.Malmberg, Karl J.Marcenaro, EmanuelaRomero, PedroBrody, RachelYuki, YukoMartin, MaureenCarrington, MaryMehrazin, RezaWiklund, PeterZhu, JunGalsky, Matthew D.Bhardwaj, NinaHorowitz, Amir
- [10] Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models[J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2023, 11 (01)Kansal, VikashBurnham, Andre J.Kinney, Brendan L. C.Saba, NabilPaulos, ChrystalLesinski, Gregory B.Buchwald, Zachary S.Schmitt, Nicole C.